A Phase 3, Multicenter, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Phase of Trial: Phase III
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs Bortezomib (Primary) ; Daratumumab; Melphalan; Prednisone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 21 Aug 2019 Planned End Date changed from 30 Sep 2023 to 28 Apr 2023.
- 30 Apr 2019 Planned End Date changed from 28 Apr 2023 to 30 Sep 2023.
- 07 Mar 2019 Planned primary completion date changed from 17 Jan 2020 to 30 Oct 2020.